Solomon Moshkevich - 02 Feb 2026 Form 4 Insider Report for Natera, Inc. (NTRA)

Role
PRESIDENT, CLINICALDIAGNOSTICS
Signature
/s/ Tami Chen, Attorney-in-Fact
Issuer symbol
NTRA
Transactions as of
02 Feb 2026
Net transactions value
-$1,072,538
Form type
4
Filing time
04 Feb 2026, 21:35:09 UTC
Previous filing
29 Jan 2026
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN /s/ Tami Chen, Attorney-in-Fact 04 Feb 2026 0002010019

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTRA Common Stock Sale $18,280 -80 -0.06% $228.50 142,406 02 Feb 2026 Direct F1
transaction NTRA Common Stock Sale $201,903 -878 -0.62% $229.96 141,528 02 Feb 2026 Direct F1, F2
transaction NTRA Common Stock Sale $132,964 -576 -0.41% $230.84 140,952 02 Feb 2026 Direct F1, F3
transaction NTRA Common Stock Sale $197,477 -850 -0.6% $232.33 140,102 02 Feb 2026 Direct F1, F4
transaction NTRA Common Stock Sale $139,942 -600 -0.43% $233.24 139,502 02 Feb 2026 Direct F1, F5
transaction NTRA Common Stock Sale $3,744 -16 -0.01% $234.00 139,486 02 Feb 2026 Direct F1
transaction NTRA Common Stock Sale $378,229 -1,639 -1.2% $230.77 137,847 03 Feb 2026 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.5700 to $230.5150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $230.6150 to $231.1400 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $231.94 to $232.92 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $232.94 to $233.82 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.